





















**Human neuraminidase inhibitors – References and unique identifiers**

| <i>Unique identifier<br/>(alternative ident)<br/><a href="#">PubChem ID</a></i> | <i>Structure</i>   | <i>Selectivity<br/>(IC<sub>50</sub> [<math>\mu</math>M])</i> | <i>References<br/>(cmpd)<sup>‡</sup></i> |
|---|--|--|--|
| DANA*<br>(Neu5Ac2en)<br><a href="#">65309</a>                                   |    | NEU3,4<br>5X<br>(8)  | 1  |
| zanamivir*<br><a href="#">60855</a>   |    | NEU2,3<br>6X<br>(8)  | 1, 2                                     |
| oseltamivir*<br><a href="#">449381</a>  |    | N/A<br>(>500)  | 1, 2                                     |
| peramivir*<br><a href="#">154234</a>  |    | NEU2<br>(70)   | 1  |
| C9-BA-DANA*<br><a href="#">71559107</a>   |  | NEU1<br>32X<br>(3)   | 3, 4<br>(10h)                            |
| CG14600<br><a href="#">145979480</a>  |  | NEU1<br>33X<br>(1)   | 4<br>(11c)                               |
| CG25900<br><a href="#">142476532</a>  |  | NEU1<br>35X<br>(0.4)   | 4<br>(11d)                               |
| CG33300<br><a href="#">145989099</a>  |  | NEU1<br>330X<br>(0.14)                                       | 4<br>(17f)                               |

|   |  |                        |                       |
|---|--|------------------------|-----------------------|
| CG33100<br><a href="#">145980895</a>                              |    | NEU1<br>220X<br>(0.40) | <sup>4</sup><br>(17g) |
| CZ28100<br>(Neu5AcN <sub>3</sub> 2en)<br><a href="#">52948463</a> |    | NEU3,4<br>4X<br>(5)    | <sup>4</sup><br>(12)  |
| CG18800<br><a href="#">145982311</a>                              |    | NEU2<br>30X<br>(4)     | <sup>4</sup><br>(13c) |
| CG32100<br><a href="#">145984892</a>                              |    | NEU2<br>7X<br>(2)      | <sup>4</sup><br>(22)  |
| CZ82100<br><a href="#">71606077</a>                               |   | NEU2<br>12X<br>(90)    | <sup>5</sup><br>(8b)  |
| CG18400<br><a href="#">145979690</a>                              |  | NEU2<br>30X<br>(3)     | <sup>4</sup><br>(13d) |
| CG11500<br><a href="#">137638962</a>                              |  | NEU3,4<br>37X<br>(1)   | <sup>6</sup><br>(7h)  |
| CZ53100<br><a href="#">71606073</a>                               |  | NEU3<br>40X<br>(24)    | <sup>5</sup><br>(5c)  |

|   |  |                        |                 |
|---|--|------------------------|-----------------|
| CG22600<br><a href="#">137660481</a>                  |    | NEU3<br>10X<br>(0.6)   | 6<br>(8b)       |
| CG19900<br><a href="#">137635553</a>                  |    | NEU3<br>40X<br>(0.6)   | 6<br>(8a)       |
| CG17700<br><a href="#">137652080</a>                  |   | NEU3,4<br>46X<br>(0.7) | 6<br>(7i)       |
| CY16600<br>(C9-4HMT-DANA)<br><a href="#">52948862</a> |  | NEU4<br>500X<br>(0.16) | 7, 8<br>(6, 6f) |

<sup>\*</sup>, compounds first reported by others; <sup>†</sup>, where applicable the compound number used in the original reference is included.

## References

- (1) Richards, M. R., Guo, T., Hunter, C. D., and Cairo, C. W. (2018) Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity. *Bioorg. Med. Chem.* 26, 5349-5358.  
<http://dx.doi.org/10.1016/j.bmc.2018.05.035>
- (2) Hata, K., Koseki, K., Yamaguchi, K., Moriya, S., Suzuki, Y., Yingsakmongkon, S., Hirai, G., Sodeoka, M., von Itzstein, M., and Miyagi, T. (2008) Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. *Antimicrob. Agents Chemother.* 52, 3484-91.  
<http://dx.doi.org/10.1128/AAC.00344-08>
- (3) Magesh, S., Moriya, S., Suzuki, T., Miyagi, T., Ishida, H., and Kiso, M. (2008) Design, synthesis, and biological evaluation of human sialidase inhibitors. Part 1: Selective inhibitors of lysosomal sialidase (NEU1). *Bioorg. Med. Chem. Lett.* 18, 532-537.  
<http://dx.doi.org/10.1016/j.bmcl.2007.11.084>
- (4) Guo, T., Heon-Roberts, R., Zou, C., Zheng, R., Pshezhetsky, A. V., and Cairo, C. W. (2018) Selective Inhibitors of Human Neuraminidase 1 (NEU1). *J. Med. Chem.* 61, 11261-11279.  
<http://dx.doi.org/10.1021/acs.jmedchem.8b01411>
- (5) Zhang, Y., Albohy, A., Zou, Y., Smutova, V., Pshezhetsky, A., and Cairo, C. W. (2013) Identification of selective inhibitors of human sialidase isoenzymes using C4, C7-modified 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) analogs. *J. Med. Chem.* 56, 2948-2958.  
<http://dx.doi.org/https://doi.org/10.1021/jm301892f>
- (6) Guo, T., Datwyler, P., Demina, E., Richards, M. R., Ge, P., Zou, C., Zheng, R., Fougerat, A., Pshezhetsky, A. V., Ernst, B., and Cairo, C. W. (2018) Selective Inhibitors of Human Neuraminidase 3. *J. Med. Chem.* 61, 1990-2008.  
<http://dx.doi.org/10.1021/acs.jmedchem.7b01574>
- (7) Albohy, A., Zhang, Y., Smutova, V., Pshezhetsky, A. V., and Cairo, C. W. (2013) Identification of Selective Nanomolar Inhibitors of the Human Neuraminidase, NEU4. *ACS Med Chem Lett* 4, 532-7. <http://dx.doi.org/10.1021/ml400080t>
- (8) Zou, Y., Albohy, A., Sandbhor, M., and Cairo, C. W. (2010) Inhibition of human neuraminidase 3 (NEU3) by C9-triazole derivatives of 2,3-didehydro-N-acetyl-neuraminic acid. *Bioorg. Med. Chem. Lett.* 20, 7529-7533. <http://dx.doi.org/10.1016/j.bmcl.2010.09.111>